Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; National Clinical Research Centre for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China.
Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231167353. doi: 10.1177/17534666231167353.
Chronic obstructive pulmonary disease (COPD) management in China is inadequate and there is a need to improve care and outcomes for patients nationwide.
The REAL study was designed to generate reliable information on COPD management from a representative sample of Chinese patients with COPD. Here, we present study outcomes related to acute exacerbations.
A 52-week, multicentre, prospective, observational study.
Outpatients (aged ⩾ 40 years) enrolled from 25 tertiary and 25 secondary hospitals across six geographic regions in China were followed for 12 months. Risk factors for COPD exacerbation and disease severity by exacerbation were assessed using multivariate Poisson and ordinal logistic regression models, respectively.
Between June 2017 and January 2019, 5013 patients were enrolled, with 4978 included in the analysis. Mean (standard deviation) age was 66.2 (8.9) years. More patients presented with exacerbations in secondary tertiary hospitals (59.4% 40.2%) and in rural urban areas (53.2% 46.3%). Overall exacerbation rates differed across regions (range: 0.27-0.84). Patients from secondary tertiary hospitals had higher rates of overall exacerbation (0.66 0.47), severe exacerbation (0.44 0.18) and exacerbation that resulted in hospitalisation (0.41 0.16). Across regions and hospital tiers, the rates of overall exacerbation and exacerbations that resulted in hospitalisation were highest in patients with very severe COPD (based on the severity of airflow limitation or GOLD 2017 combined assessment). Strong predictors of exacerbation included demographic and clinical characteristics, modified Medical Research Council scores, mucus purulence, exacerbation history and the use of maintenance mucolytic treatment.
COPD exacerbation rates varied across regions and were higher in secondary compared with tertiary hospitals in China. Understanding the factors associated with COPD exacerbation may facilitate improved management of COPD exacerbations in China.
The trial was registered on 20 March 2017 (ClinicalTrials.gov: NCT03131362; https://clinicaltrials.gov/ct2/show/NCT03131362).
Chronic obstructive pulmonary disease (COPD) causes progressive and irreversible airflow limitation. As the disease progresses, patients often experience a flare up of symptoms referred to as an exacerbation. There is inadequate management of COPD in China and, therefore, there is a need to improve care and outcomes for patients across the country. This study aimed to generate reliable information on exacerbations among Chinese patients with COPD to help inform future management strategies. Patients (aged ⩾ 40 years) were enrolled from 25 secondary and 25 tertiary hospitals across six regions of China. Physicians collected data over 1 year during routine outpatient visits. There were more patients who experienced an exacerbation in secondary tertiary hospitals (59% 40%) and in rural urban areas (53% 46%). Patients in different geographic regions experienced varying frequencies of exacerbations over 1 year. Compared with patients from tertiary hospitals, patients from secondary hospitals experienced exacerbations (including exacerbations that were severe and those that resulted in hospitalisation) at a higher frequency over 1 year. Patients with very severe disease experienced exacerbations (including exacerbations that resulted in hospitalisation) at the highest frequency over 1 year, regardless of the patient's geographic region or hospital tier. Patients who had certain characteristics and symptoms, had exacerbation(s) over the previous year, or received medication that aids in the clearance of mucus were more likely to experience exacerbations. The frequency of exacerbations among Chinese patients with COPD varied between patients living in different geographic regions and between patients presenting to different hospital tiers. Understanding the factors related to the occurrence of an exacerbation may help physicians better manage the disease.
中国的慢性阻塞性肺疾病(COPD)管理不足,需要改善全国范围内患者的护理和结局。
REAL 研究旨在从中国 COPD 患者的代表性样本中获取有关 COPD 管理的可靠信息。在这里,我们介绍与急性加重相关的研究结果。
一项 52 周、多中心、前瞻性、观察性研究。
从中国六个地理区域的 25 家三级和 25 家二级医院招募年龄≥40 岁的门诊患者,随访 12 个月。使用多元泊松和有序逻辑回归模型评估 COPD 加重的危险因素和疾病严重程度。
2017 年 6 月至 2019 年 1 月期间,共纳入 5013 例患者,其中 4978 例纳入分析。患者的平均(标准差)年龄为 66.2(8.9)岁。更多患者在二级或三级医院(59.4%比 40.2%)和农村或城市地区(53.2%比 46.3%)出现加重。各地区的总体加重率不同(范围:0.27-0.84)。二级或三级医院的患者总体加重(0.66比 0.47)、严重加重(0.44比 0.18)和加重导致住院的发生率(0.41比 0.16)更高。在不同地区和医院层级中,基于气流受限严重程度或 2017 年 GOLD 联合评估的严重程度,严重 COPD 患者的总体加重和加重导致住院的发生率最高。加重的强烈预测因素包括人口统计学和临床特征、改良医学研究理事会评分、黏液脓性、加重史和维持黏液溶解治疗的使用。
中国 COPD 加重率因地区而异,二级医院高于三级医院。了解 COPD 加重的相关因素可能有助于改善中国 COPD 加重的管理。
该试验于 2017 年 3 月 20 日在 ClinicalTrials.gov 注册(注册号:NCT03131362;网址:https://clinicaltrials.gov/ct2/show/NCT03131362)。